Abdulkarim Abdulrahman1,2, Islam AlSayed3, Marwa AlMadhi4, Jumana AlArayed5, Sara Jaafar Mohammed3, Aesha Khalid Sharif5, Khadija Alansari3, Abdulla Ismael AlAwadhi1,6, Manaf AlQahtani7,8,9. 1. National Taskforce for Combating the Coronavirus (COVID-19), Manama, Bahrain. 2. Mohammed Bin Khalifa Cardiac Centre, Riffa, Bahrain. 3. King Hamad University Hospital, Busaiteen, Bahrain. 4. School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. 5. Ministry of Health, Manama, Bahrain. 6. Bahrain Defence Force Hospital, Riffa, Bahrain. 7. National Taskforce for Combating the Coronavirus (COVID-19), Manama, Bahrain. mqahtani@rcsi-mub.com. 8. Bahrain Defence Force Hospital, Riffa, Bahrain. mqahtani@rcsi-mub.com. 9. Royal College of Surgeons in Ireland - Bahrain, Busaiteen, Bahrain. mqahtani@rcsi-mub.com.
Abstract
INTRODUCTION: Hydroxychloroquine (HCQ) is an antimalarial drug that received worldwide news and media attention in the treatment of patients with coronavirus disease 2019 (COVID-19). This drug was used on the basis of its antimicrobial and antiviral properties despite lack of definite evidence of clinical efficacy. In this study, we aim to assess the efficacy and safety of using HCQ in treatment of patients with COVID-19 who were admitted in acute care hospitals in Bahrain. METHODS: We conducted a retrospective cohort study on a random sample of patients admitted with COVID-19 between 24 February and 31 July 2020. The study was conducted in four acute care COVID-19 hospitals in Bahrain. Data was extracted from the medical records. The primary endpoint was the requirement of non-invasive ventilation, intubation, or death. Secondary endpoint was length of hospitalization for survivors. Three methods of analysis were used to control for confounding factors: logistic multivariate regression, propensity score adjusted regression, and matched propensity score analysis. RESULTS: A random sample of 1571 patients were included, 440 of whom received HCQ (treatment group) and 1131 did not receive it (control group). Our results showed that HCQ did not have a significant effect on primary outcomes due to COVID-19 infection when compared to controls after adjusting for confounders (OR 1.43, 95% CI 0.85-2.37, P = 0.17). Co-administration of azithromycin had no effect on primary outcomes (OR 2.7, 95% CI 0.82-8.85, P = 0.10). HCQ was associated with increased risk of hypoglycemia (OR 10.9, 95% CI 1.72-69.49, P = 0.011) and diarrhea (OR 2.8, 95% CI 1.4-5.5, P = 0.003), but not QT prolongation (OR 1.92, 95% CI 0.95-3.9, P = 0.06) or cardiac arrhythmia (OR 1.06, 95% CI 0.55-2.05, P = 0.85). CONCLUSION: Our results showed no significant beneficial effect of using hydroxychloroquine on the outcome of patients with COVID-19. Moreover, the risk of hypoglycemia due to hydroxychloroquine would possess a significant risk for out-of-hospital use.
INTRODUCTION:Hydroxychloroquine (HCQ) is an antimalarial drug that received worldwide news and media attention in the treatment of patients with coronavirus disease 2019 (COVID-19). This drug was used on the basis of its antimicrobial and antiviral properties despite lack of definite evidence of clinical efficacy. In this study, we aim to assess the efficacy and safety of using HCQ in treatment of patients with COVID-19 who were admitted in acute care hospitals in Bahrain. METHODS: We conducted a retrospective cohort study on a random sample of patients admitted with COVID-19 between 24 February and 31 July 2020. The study was conducted in four acute care COVID-19 hospitals in Bahrain. Data was extracted from the medical records. The primary endpoint was the requirement of non-invasive ventilation, intubation, or death. Secondary endpoint was length of hospitalization for survivors. Three methods of analysis were used to control for confounding factors: logistic multivariate regression, propensity score adjusted regression, and matched propensity score analysis. RESULTS: A random sample of 1571 patients were included, 440 of whom received HCQ (treatment group) and 1131 did not receive it (control group). Our results showed that HCQ did not have a significant effect on primary outcomes due to COVID-19infection when compared to controls after adjusting for confounders (OR 1.43, 95% CI 0.85-2.37, P = 0.17). Co-administration of azithromycin had no effect on primary outcomes (OR 2.7, 95% CI 0.82-8.85, P = 0.10). HCQ was associated with increased risk of hypoglycemia (OR 10.9, 95% CI 1.72-69.49, P = 0.011) and diarrhea (OR 2.8, 95% CI 1.4-5.5, P = 0.003), but not QT prolongation (OR 1.92, 95% CI 0.95-3.9, P = 0.06) or cardiac arrhythmia (OR 1.06, 95% CI 0.55-2.05, P = 0.85). CONCLUSION: Our results showed no significant beneficial effect of using hydroxychloroquine on the outcome of patients with COVID-19. Moreover, the risk of hypoglycemia due to hydroxychloroquine would possess a significant risk for out-of-hospital use.
Authors: Rebecca M Mingo; James A Simmons; Charles J Shoemaker; Elizabeth A Nelson; Kathryn L Schornberg; Ryan S D'Souza; James E Casanova; Judith M White Journal: J Virol Date: 2014-12-31 Impact factor: 5.103
Authors: Joshua Geleris; Yifei Sun; Jonathan Platt; Jason Zucker; Matthew Baldwin; George Hripcsak; Angelena Labella; Daniel K Manson; Christine Kubin; R Graham Barr; Magdalena E Sobieszczyk; Neil W Schluger Journal: N Engl J Med Date: 2020-05-07 Impact factor: 91.245
Authors: Philippe Gautret; Jean-Christophe Lagier; Philippe Parola; Van Thuan Hoang; Line Meddeb; Morgane Mailhe; Barbara Doudier; Johan Courjon; Valérie Giordanengo; Vera Esteves Vieira; Hervé Tissot Dupont; Stéphane Honoré; Philippe Colson; Eric Chabrière; Bernard La Scola; Jean-Marc Rolain; Philippe Brouqui; Didier Raoult Journal: Int J Antimicrob Agents Date: 2020-03-20 Impact factor: 5.283
Authors: Ying Zhao; Jingru Zhang; Kai Zheng; Sydney Thai; Ross J Simpson; Alan C Kinlaw; Yang Xu; Jingkai Wei; Xiangli Cui; John B Buse; Til Stürmer; Tiansheng Wang Journal: Drugs Real World Outcomes Date: 2022-04-06